Bile Acid Binding Resin Improves Metabolic Control through the Induction of Energy Expenditure
暂无分享,去创建一个
J. Auwerx | Kohkichi Morimoto | H. Itoh | S. Houten | K. Schoonjans | C. Mataki | Mitsuhiro Watanabe | Hiroyuki Sato | Tatsuya Suzuki | T. Sugizaki | Karin Murahashi | Yasushi Horai | Eri Arita | Nao Kaneko-Iwasaki | Taichi Sugizaki
[1] H. Nakano,et al. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. , 2012, Journal of diabetes and its complications.
[2] M. Orešič,et al. Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.
[3] J. Auwerx,et al. Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.
[4] F. Kuipers,et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism , 2010, Hepatology.
[5] M. Manns,et al. Plasma bile acids are not associated with energy metabolism in humans , 2010, Nutrition & metabolism.
[6] F. Gonzalez,et al. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice , 2010, Laboratory Investigation.
[7] M. Ruth. Cold-Activated Brown Adipose Tissue in Healthy Men , 2010 .
[8] J. Orava,et al. Functional brown adipose tissue in healthy adults. , 2009, The New England journal of medicine.
[9] J. Auwerx,et al. TGR5-mediated bile acid sensing controls glucose homeostasis. , 2009, Cell metabolism.
[10] E. Palmer,et al. Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.
[11] R. Goldberg,et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. , 2008, Archives of internal medicine.
[12] J. Rosenstock,et al. Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy , 2008, Diabetes Care.
[13] R. Goldberg,et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. , 2008, Archives of internal medicine.
[14] J. Auwerx,et al. Compromised Intestinal Lipid Absorption in Mice with a Liver-Specific Deficiency of Liver Receptor Homolog 1 , 2007, Molecular and Cellular Biology.
[15] T. Ogihara,et al. Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin , 2007, Diabetes.
[16] S. Schwartz,et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. , 2007, Clinical therapeutics.
[17] J. Auwerx,et al. Endocrine functions of bile acids , 2006, The EMBO journal.
[18] J. Auwerx,et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.
[19] S. Kliewer,et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.
[20] G. Tsujimoto,et al. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. , 2005, Biochemical and biophysical research communications.
[21] Sander M Houten,et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.
[22] J. Auwerx,et al. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts , 2004, Annals of medicine.
[23] D. Russell. The enzymes, regulation, and genetics of bile acid synthesis. , 2003, Annual review of biochemistry.
[24] S. Kliewer,et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.
[25] Masataka Harada,et al. A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.
[26] P. Puigserver,et al. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.
[27] J. Auwerx,et al. SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues , 2002, Cell.
[28] Takao Nakamura,et al. Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.
[29] J. Auwerx,et al. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. , 2002, Molecular endocrinology.
[30] D. Russell,et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. , 2002, Developmental cell.
[31] M. Karin,et al. Redundant pathways for negative feedback regulation of bile acid production. , 2002, Developmental cell.
[32] D. French,et al. Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .
[33] P. Larsen,et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. , 2002, Endocrine reviews.
[34] Masahiro Tohkin,et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.
[35] T. A. Kerr,et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.
[36] L. Moore,et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.
[37] M. Makishima,et al. Identification of a nuclear receptor for bile acids. , 1999, Science.
[38] J. Lehmann,et al. Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.
[39] Jasmine Chen,et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.
[40] H. Yamaguchi,et al. Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. , 1997, Atherosclerosis.
[41] S. Grundy,et al. Cholestyramine Therapy for Dyslipidemia in NonInsulin-dependent Diabetes Mellitus: A Short-Term, Double-Blind, Crossover Trial , 1994, Annals of Internal Medicine.
[42] M. Maeda,et al. Simultaneous determination of bile acids in rat bile and serum by high-performance liquid chromatography. , 1993, Journal of chromatography.
[43] G. Bray,et al. Effects of cholecystokinin on sympathetic activity to interscapular brown adipose tissue , 1992, Brain Research.
[44] G. Greeley,et al. Chronic Effect of Oral Cholestyramine, a Bile Salt Sequestrant, and Exogenous Cholecystokinin on Insulin Release in Rats , 1992, Pancreas.
[45] T. Nagasaka,et al. Changes in brown adipose tissue metabolism following intraventricular vasoactive intestinal peptide and other gastrointestinal peptides in rats. , 1989, The Japanese Journal of Physiology.
[46] A. Fellgiebel,et al. Effect of cholestyramine on plasma cholecystokinin and pancreatic polypeptide levels, and exocrine pancreatic secretion , 1988, European journal of clinical investigation.
[47] J. Garbutt,et al. Effect of cholestyramine on bile acid metabolism in normal man. , 1972, The Journal of clinical investigation.
[48] J. Folch,et al. A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.